Clinical Trials

160 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04310007 2026-04-13

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

117 enrolled

Lung Neoplasms

NCT06448754 2026-04-13

eVOLVE-01

180 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05980000 2026-03-31

Rambro2

37 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05999994 2026-03-27

CAMPFIRE

105 enrolled

Tumor-Agnostic

Neoplasms

NCT03686488 2026-03-02

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Phase 2 Completed

23 enrolled 12 charts

Stomach Neoplasms

NCT07098338 2026-02-05

LIBRA

278 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04340882 2026-01-30

DoceRamPem

30 enrolled

Lung Neoplasms

NCT06031688 2026-01-23

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

56 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03527108 2026-01-14

Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC

36 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04332367 2026-01-07

Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

59 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05642572 2025-12-05

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

66 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06251973 2025-12-02

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

37 enrolled

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

NCT04205968 2025-11-05

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

94 enrolled

Metastatic Small Intestinal Adenocarcinoma

NCT03694002 2025-10-30

Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

Phase 2 Completed

21 enrolled 17 charts

Thymoma

NCT05071053 2025-08-22

CARMEN-GC01

Phase 2 Terminated

35 enrolled 14 charts

Adenocarcinoma Gastric

NCT02711553 2025-08-03

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

309 enrolled 22 charts

Biliary Tract Neoplasms, Neoplasm Metastasis

NCT06038578 2025-08-03

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

146 enrolled

Adenocarcinoma, Stomach Neoplasms

NCT04069273 2025-07-31

SEQUEL

58 enrolled

Adenocarcinoma, Stomach Neoplasms

NCT04120454 2025-07-11

Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer

Phase 2 Completed

6 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02678182 2025-06-10

PLATFORM

494 enrolled

Adenocarcinoma of the Oesophagus

NCT04394624 2025-06-06

CARMEN-LC04

Phase 2 Terminated

31 enrolled 22 charts

Non-small Cell Lung Cancer Metastatic

NCT05311176 2025-05-11

nextHERIZON

Phase 2 Terminated

7 enrolled 8 charts